Astellas nabs NIH grant to fund studies of opioid addiction therapy

NIH’s National Institute on Drug Abuse has awarded a grant to Astellas Pharma (OTCPK:ALPMF) to help fund two Phase 1 clinical trials testing the safety and efficacy of ASP8062, an oral small molecule GABA_B receptor Positive Allosteric Modulator, as add-on maintenance therapy for opioid use disorder (OUD).

If the results are positive, a second phase of the grant may be awarded to help fund a randomized Phase 2 study in OUD patients on stable buprenorphine-based therapy.

https://seekingalpha.com/news/3593633-astellas-nabs-nih-grant-to-fund-studies-of-opioid-addiction-therapy